SciVision Biotech Inc - Asset Resilience Ratio
SciVision Biotech Inc (1786) has an Asset Resilience Ratio of 6.42% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 1786 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how SciVision Biotech Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SciVision Biotech Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down SciVision Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore SciVision Biotech Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$176.58 Million | 6.42% |
| Total Liquid Assets | NT$176.58 Million | 6.42% |
Asset Resilience Insights
- Limited Liquidity: SciVision Biotech Inc maintains only 6.42% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SciVision Biotech Inc Industry Peers by Asset Resilience Ratio
Compare SciVision Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.87% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Autek China Inc
SHE:300595 |
Medical Instruments & Supplies | 21.20% |
|
Jiangxi Sanxin Medtec Co Ltd
SHE:300453 |
Medical Instruments & Supplies | 13.70% |
|
QITIAN Technology Group Co Ltd
SHE:300061 |
Medical Instruments & Supplies | 0.00% |
|
Dentium
KO:145720 |
Medical Instruments & Supplies | 1.23% |
|
Interojo Inc
KQ:119610 |
Medical Instruments & Supplies | 6.55% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
Annual Asset Resilience Ratio for SciVision Biotech Inc (2011–2025)
The table below shows the annual Asset Resilience Ratio data for SciVision Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.81% | NT$208.55 Million ≈ $6.57 Million |
NT$2.67 Billion ≈ $84.11 Million |
+0.79pp |
| 2024-12-31 | 7.03% | NT$165.40 Million ≈ $5.21 Million |
NT$2.35 Billion ≈ $74.18 Million |
-6.54pp |
| 2023-12-31 | 13.56% | NT$292.95 Million ≈ $9.23 Million |
NT$2.16 Billion ≈ $68.06 Million |
+9.42pp |
| 2022-12-31 | 4.14% | NT$86.87 Million ≈ $2.74 Million |
NT$2.10 Billion ≈ $66.11 Million |
+2.51pp |
| 2021-12-31 | 1.63% | NT$36.92 Million ≈ $1.16 Million |
NT$2.26 Billion ≈ $71.26 Million |
+0.79pp |
| 2020-12-31 | 0.84% | NT$15.94 Million ≈ $502.29K |
NT$1.89 Billion ≈ $59.57 Million |
-4.38pp |
| 2019-12-31 | 5.23% | NT$97.29 Million ≈ $3.07 Million |
NT$1.86 Billion ≈ $58.66 Million |
+4.27pp |
| 2018-12-31 | 0.96% | NT$16.21 Million ≈ $510.70K |
NT$1.70 Billion ≈ $53.43 Million |
-0.09pp |
| 2017-12-31 | 1.05% | NT$16.37 Million ≈ $515.84K |
NT$1.56 Billion ≈ $49.25 Million |
-9.27pp |
| 2016-12-31 | 10.32% | NT$140.02 Million ≈ $4.41 Million |
NT$1.36 Billion ≈ $42.76 Million |
-11.64pp |
| 2015-12-31 | 21.96% | NT$235.55 Million ≈ $7.42 Million |
NT$1.07 Billion ≈ $33.80 Million |
-9.14pp |
| 2014-12-31 | 31.10% | NT$339.61 Million ≈ $10.70 Million |
NT$1.09 Billion ≈ $34.40 Million |
+13.56pp |
| 2013-12-31 | 17.54% | NT$198.03 Million ≈ $6.24 Million |
NT$1.13 Billion ≈ $35.57 Million |
-10.72pp |
| 2012-12-31 | 28.26% | NT$136.59 Million ≈ $4.30 Million |
NT$483.28 Million ≈ $15.23 Million |
-5.31pp |
| 2011-12-31 | 33.58% | NT$135.61 Million ≈ $4.27 Million |
NT$403.87 Million ≈ $12.72 Million |
-- |
About SciVision Biotech Inc
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was fo… Read more